evogliptin
Ligand Summary
Evogliptin is an orally bioavailable, selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus. DPP-4 inhibitors control glucose levels by preventing the breakdown of the incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), which stimulate insulin secretion in response to the increased levels of glucose in the period following meals.
UNII: 09118300L7
PubChem: 25022354
ChEMBL: CHEMBL1779710
DrugCentral: 5239
LyCHI: 8XG3Z4M9HZY6
Target Activities
2 Activities
Items per page:
10
1 – 2 of 2
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
---|---|---|---|---|---|---|
IC50 | ||||||
IC50 | INHIBITOR | |||||